Minipool Caprylic Acid Fractionation of Plasma Using Disposable Equipment: A Practical Method to Enhance Immunoglobulin Supply in Developing Countries

PLoS Neglected Tropical Diseases

Volumn 9, Issue 2, 2015, Pages

  El Ekiaby, Magdy ^a   Vargas, Mariángela ^b   Sayed, Makram ^c   Gorgy, George ^a   Goubran, Hadi ^d   Radosevic, Mirjana ^e   Burnouf, Thierry ^f  

^a Shabrawishy Hospital   (Egypt)

^b UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^c FAYOUM UNIVERSITY   (Egypt)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e HUMAN PROTEIN PROCESS SCIENCES   (France)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; OCTANOIC ACID; OCTANOIC ACID DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; COST; DRUG ACTIVITY; DRUG CARCINOGENICITY; DRUG MANUFACTURE; DRUG SAFETY; EGYPT; HEPATITIS B; HUMAN; IMMUNE DEFICIENCY; NONHUMAN; PLASMA; PROTEIN ANALYSIS; RUBELLA; ANIMAL; BLOOD; BLOOD BANK; BLOOD DONOR; CHEMISTRY; DEVELOPING COUNTRY; DEVICES; DISPOSABLE EQUIPMENT; FEMALE; FRACTIONATION; HEMORRHAGIC FEVER, EBOLA; ISOLATION AND PURIFICATION; RAT;

ANIMALS; BLOOD BANKS; BLOOD DONORS; CAPRYLATES; CHEMICAL FRACTIONATION; DEVELOPING COUNTRIES; DISPOSABLE EQUIPMENT; EGYPT; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNOGLOBULIN G; PLASMA; RATS;

EID: 84924078767     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003501     Document Type: Article

References (40)

1. Burnouf T, (2007) Modern plasma fractionation. Transfus Med Rev 21: 101–117. 17397761
2. El-Ekiaby M, Sayed MA, Caron C, Burnouf S, El-Sharkawy N, et al. (2010) Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transfus Med 20: 48–61. doi: 10.1111/j.1365-3148.2009.00963.x 19778318
3. Burnouf T, Goubran HA, Radosevich M, Sayed MA, Gorgy G, et al. (2006) A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system. Vox Sang 91: 56–62. 16756602
4. Burnouf T, Goubran HA, Radosevich M, Sayed MA, Gorgy G, et al. (2006) A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system. Transfusion 46: 2100–2108. 17176321
5. Gulland A, (2014) First Ebola treatment is approved by WHO. British Medical Journal 349: g5539. doi: 10.1136/bmj.g5539 25200068
6. Burnouf T, Emmanuel J, Mbanya D, El-Ekiaby M, Murphy W, et al. (2014) Ebola: a call for blood transfusion strategy in sub-Saharan Africa. Lancet 384: 1347–1348. doi: 10.1016/S0140-6736(14)61693-7 25277678
7. Burnouf T, Caron C, Radosevich M, Goubran HA, Goudemand J, et al. (2008) Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems. Haemophilia 14: 956–962. doi: 10.1111/j.1365-2516.2008.01797.x 18565126
8. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685. 5432063
9. Wu YW, Champagne J, Toueille M, Gantier R, Burnouf T, (2014) Dedicated removal of immunoglobulin (Ig)A, IgM, and Factor (F)XI/activated FXI from human plasma IgG. Transfusion 54: 169–178. doi: 10.1111/trf.12243 23701287
10. Vargas M, Segura A, Wu Y-W, Herrera M, Chou M-L, et al. (2015) Human plasma-derived immunoglobulin G fractionated by an aqueous two-phase system, caprylic acid precipitation, and membrane chromatography has a high purity level and is free of detectable in vitro thrombogenic activity. Vox Sang doi: 10.1111/vox.12218 25471135
11. CPMP (1996) Note for Guidance on Virus Validation Studies: the Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses (revised). CPMP/BWP/CPMP/5136/03. http://www.emea.eu.int. London: European Agency for the Evaluation of Medicinal Products (EMEA).
12. Radosevich M, Burnouf T, (2010) Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sanguinis 98: 12–28. doi: 10.1111/j.1423-0410.2009.01226.x 19660029
13. Farrugia A, Evers T, Falcou PF, Burnouf T, Amorim L, et al. (2009) Plasma fractionation issues. Biologicals 37: 88–93. doi: 10.1016/j.biologicals.2009.01.005 19289290
14. Habeeb AF, Francis RD, (1984) Preparation of human immunoglobulin by caprylic acid precipitation. Prep Biochem 14: 1–17. 6718324
15. Steinbuch M, Audran R, (1969) [Isolation of IgG immunoglobulin from human plasma using caprylic acid]. Rev Fr Etud Clin Biol 14: 1054–1058. 5377892
16. Parkkinen J, Rahola A, von Bonsdorff L, Tolo H, Torma E, (2006) A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance. Vox Sang 90: 97–104. 16430667
17. Lebing W, Remington KM, Schreiner C, Paul HI, (2003) Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography. Vox Sang 84: 193–201. 12670368
18. Dichtelmüller H, Rudnick D, Kloft M, (2002) Inactivation of Lipid Enveloped Viruses by Octanoic Acid Treatment of Immunoglobulin Solution. Biologicals 30: 135–142. 12127315
19. Rojas G, Jimenez JM, Gutierrez JM, (1994) Caprylic acid fractionation of hyperimmune horse plasma: description of a simple procedure for antivenom production. Toxicon 32: 351–363. 8016856
20. Otero R, Gutierrez JM, Rojas G, Nunez V, Diaz A, et al. (1999) A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia: correlation between safety and biochemical characteristics of antivenoms. Toxicon 37: 895–908. 10340829
21. Brodsky Y, Zhang C, Yigzaw Y, Vedantham G, (2012) Caprylic acid precipitation method for impurity reduction: an alternative to conventional chromatography for monoclonal antibody purification. Biotechnol Bioeng 109: 2589–2598. doi: 10.1002/bit.24539 22549395
22. Sandler SG, Eder AF, Goldman M, Winters JL, (2014) The entity of immunoglobulin A-related anaphylactic transfusion reactions is not evidence based. Transfusion doi: 10.1111/trf.12981 25556575
23. Heger A, Brandstatter H, Prager B, Brainovic J, Cortes R, et al. (2014) Universal pooled plasma (Uniplas) does not induce complement-mediated hemolysis of human red blood cells in vitro. Transfus Apher Sci doi: 10.1016/j.transci.2014.12.028 25620758
24. Daniel GW, Menis M, Sridhar G, Scott D, Wallace AE, et al. (2012) Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010. Transfusion 52: 2113–2121. doi: 10.1111/j.1537-2995.2012.03589.x 22448967
25. Roemisch JR, Kaar W, Zoechling A, Kannicht C, Putz M, et al. (2011) Identification of activated FXI as the major biochemical root cause in IVIG batches associated with thromboembolic events. Analytical and experimental approaches resulting in corrective and preventive measures implemented into the Octagam® manufacturing process. Immunotherapy 2011;2:WMC002002.
26. Commission EP, Anonymous (2012) Monograph on human normal immunoglobulin for intravenous administration (0918): 01/2012, European Pharmacopoeia, Strasbourg (France), Council of Europe, 2012. In: Strasbourg, France: Council of Europe European Department for the Quality of Medicines.
27. FDA-Workshop (2011) Risk mitigation strategies to address potential procoagulant activity in immune globulin products. In: Administration FD, editor. http://wwwfdagov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/UCM258022pdf.
28. Germishuizen WA, Gyure DC, Stubbings D, Burnouf T, (2014) Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products. Biologicals 42: 260–270. doi: 10.1016/j.biologicals.2014.04.002 25096922
29. WHO (2005) Recommendations for the production, quality control and regulation of plasma for fractionation. http://www.who.int/bloodproducts.
30. Burnouf T, Radosevich M, (2000) Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev 14: 94–110. 11012252
31. El Ekiaby M, Lelie N, Allain JP, (2010) Nucleic acid testing (NAT) in high prevalence-low resource settings. Biologicals 38: 59–64. doi: 10.1016/j.biologicals.2009.10.015 20079664
32. WHO (2003) Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. http://www.WHO.int/bloodproducts. Geneva. 1–72 p. doi: 10.1016/S1471-5953(02)00116-6 19036311
33. Korneyeva M, Hotta J, Lebing W, Rosenthal RS, Franks L, et al. (2002) Enveloped virus inactivation by caprylate: A robust alternative to solvent-detergent treatment in plasma derived intermediates. Biologicals 30: 153–162. 12127317
34. Mpandi M, Schmutz P, Legrand E, Duc R, Geinoz J, et al. (2007) Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins. Biologicals 35: 335–341. 17470396
35. Burnouf T, Terpstra F, Habib G, Seddik S, (2007) Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms. Biologicals 35: 329–334. 17363271
36. Caricati CP, Oliveira-Nascimento L, Yoshida JT, Caricati AT, Raw I, et al. (2013) Safety of snake antivenom immunoglobulins: efficacy of viral inactivation in a complete downstream process. Biotechnol Prog 29: 972–979. doi: 10.1002/btpr.1758 23804299
37. Burnouf T, Radosevich M, (2003) Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 9: 24–37. 12558776
38. Segura A, Leon G, Su CY, Gutierrez JM, Burnouf T, (2009) Assessment of the impact of solvent/detergent treatment on the quality and potency of a whole IgG equine antivenom. Biologicals 37: 306–312. doi: 10.1016/j.biologicals.2009.05.003 19540775
39. Burnouf T, (2014) New approaches for manufacturing plasma derivatives. ISBT Science Series 9: 160–167.
40. Burnouf T, Seghatchian J, (2014) Ebola virus convalescent blood products: Where we are now and where we may need to go. Transfus Apher Sci 51: 120–125. 25457751